Basic Information
| LncRNA/CircRNA Name | ANRIL |
| Synonyms | CDKN2B-AS1, ANRIL, CDKN2B-AS, CDKN2BAS, NCRNA00089, PCAT12, p15AS |
| Region | GRCh38_9:21994778-22121097 |
| Ensemble | ENSG00000240498 |
| Refseq | NR_003529 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | non small cell lung cancer |
| ICD-0-3 | C34 |
| Methods | qPCR etc. |
| Sample | non-small cell lung cancer tissues |
| Expression Pattern | up-regulated |
| Function Description | We assessed the expressions of the 12 lncRNAs in 92 serum samplesand identified two lncRNAs [SOX2OT and ANRIL] that were overexpressed in tumor serum samples compared with healthy controls. Kaplan-Meier analysis demonstrated that low expressions of SOX3OT and ANRIL were both associated with higher OS rate (P = 0.008 and 0.017, respectively), and SOX2OT could be used as an independent prognostic factor (P = 0.036). |
| Pubmed ID | 29504701 |
| Year | 2018 |
| Title | Circulating long noncoding RNA act as potential novel biomarkers for diagnosis and prognosis of non-small cell lung cancer. |
External Links
| Links for ANRIL | GenBank HGNC NONCODE |
| Links for non small cell lung cancer | OMIM COSMIC |